Eskalith CR (lithium carbonate)
SmithKline Beecham notifies health professionals that effective immediately, they will distribute Eskalith CR controlled release 450 mg tablets from an alternate manufacturing facility. The previously approved manufacturing facility is no longer producing Eskalith CR 450 mg tablets. Product produced at the new facility has been shown to be equivalent to Eskalith CR 450 mg tablets manufactured at the previously approved site; however, long-term stability data is still being collected on this product.
[March 2000 - Letter - SmithKline Beecham]